NASDAQ:TXG 10x Genomics (TXG) Stock Forecast, Price & News $54.60 +1.40 (+2.63%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$53.58▼$55.3650-Day Range$48.90▼$57.1052-Week Range$23.81▼$58.30Volume923,092 shsAverage Volume976,004 shsMarket Capitalization$6.34 billionP/E RatioN/ADividend YieldN/APrice Target$54.85 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability 10x Genomics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside0.5% Upside$54.85 Price TargetShort InterestHealthy4.73% of Shares Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.94Based on 7 Articles This WeekInsider TradingSelling Shares$2.32 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.39) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector654th out of 983 stocksAnalytical Instruments Industry17th out of 27 stocks 1.3 Analyst's Opinion Consensus Rating10x Genomics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 8 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.85, 10x Genomics has a forecasted upside of 0.5% from its current price of $54.60.Amount of Analyst Coverage10x Genomics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.73% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in 10x Genomics has recently decreased by 8.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) Score10x Genomics has received a 77.86% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for 10x Genomics is -0.89. Previous Next 2.7 News and Social Media Coverage News Sentiment10x Genomics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for 10x Genomics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,323,824.00 in company stock.Percentage Held by Insiders11.08% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.34% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.39) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -35.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -35.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 7.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 10x Genomics (NASDAQ:TXG) Stock10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Stock News HeadlinesJune 1, 2023 | finance.yahoo.com10x Genomics Files Two New Lawsuits Requesting Preliminary Injunctions Against NanoString's CosMx ProductsMay 31, 2023 | morningstar.com10x Genomics Inc Ordinary Shares - Class AJune 3, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 27, 2023 | americanbankingnews.comJustin J. Mcanear Sells 1,665 Shares of 10x Genomics, Inc. (NASDAQ:TXG) StockMay 27, 2023 | americanbankingnews.comBenjamin J. Hindson Sells 2,388 Shares of 10x Genomics, Inc. (NASDAQ:TXG) StockMay 25, 2023 | finance.yahoo.comHow 10x Genomics Provides A View Into The Body's Cellular WarfareMay 24, 2023 | finance.yahoo.com10x Genomics Launches Visium CytAssist Gene and Protein Expression AssayMay 24, 2023 | finance.yahoo.com10x Genomics, Inc. (NASDAQ:TXG) Not Flying Under The RadarJune 3, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 24, 2023 | americanbankingnews.com10x Genomics (NASDAQ:TXG) Reaches New 52-Week High at $57.88May 24, 2023 | americanbankingnews.comSerge Saxonov Sells 2,602 Shares of 10x Genomics, Inc. (NASDAQ:TXG) StockMay 23, 2023 | bizjournals.com10x Genomics opens new R&D, operations center in PleasantonMay 19, 2023 | msn.comStephens & Co. Reiterates 10x Genomics Inc - (TXG) Overweight RecommendationMay 19, 2023 | americanbankingnews.comSerge Saxonov Sells 2,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG) StockMay 18, 2023 | msn.com7 Analysts Have This to Say About 10x GenomicsMay 18, 2023 | finance.yahoo.comWhy Are NanoString Technologies Shares Falling TodayMay 18, 2023 | msn.comNanoString Tanks after 10x Genomics Wins Injunction in Patent Lawsuit in GermanyMay 18, 2023 | finance.yahoo.comWhy Shares of NanoString Technologies Are Falling ThursdayMay 17, 2023 | seekingalpha.comNanoString slips after German court awards injunction against its products to 10x GenomicsMay 17, 2023 | finance.yahoo.com10x Genomics Wins Permanent Injunction Against NanoString's CosMx ProductsMay 17, 2023 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) Director Mathai Mammen Sells 33,000 SharesMay 14, 2023 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) Receives $54.85 Average Price Target from AnalystsMay 12, 2023 | msn.com10x Genomics draws Overweight rating at Barclays on business transformationMay 11, 2023 | americanbankingnews.com10x Genomics (NASDAQ:TXG) Receives New Coverage from Analysts at BarclaysMay 10, 2023 | msn.comBarclays Initiates Coverage of 10x Genomics Inc - (TXG) with Overweight RecommendationMay 10, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for 10x Genomics, Inc.'s Q2 2023 Earnings (NASDAQ:TXG)May 8, 2023 | americanbankingnews.com10x Genomics (NASDAQ:TXG) Price Target Raised to $68.00See More Headlines TXG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXG Company Calendar Last Earnings5/03/2023Today6/02/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXG CUSIPN/A CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,239Year FoundedN/APrice Target and Rating Average Stock Price Forecast$54.85 High Stock Price Forecast$68.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+0.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,000,000.00 Net Margins-32.51% Pretax Margin-31.69% Return on Equity-22.02% Return on Assets-17.26% Debt Debt-to-Equity RatioN/A Current Ratio5.37 Quick Ratio4.64 Sales & Book Value Annual Sales$516.41 million Price / Sales12.28 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book7.90Miscellaneous Outstanding Shares116,190,000Free Float103,318,000Market Cap$6.34 billion OptionableOptionable Beta1.75 Key ExecutivesDr. Serge Saxonov Ph.D. (Age 46)Co-Founder, CEO & Director Comp: $736.52kDr. Benjamin J. Hindson Ph.D. (Age 48)Co-Founder, Pres, Chief Scientific Officer & Director Comp: $496kMr. Justin J. McAnear (Age 47)Chief Financial Officer Comp: $470.4kMr. Eric S. Whitaker Esq. (Age 56)Chief Legal Officer Comp: $505kMr. Michael Schnall-LevinFounding Scientist & CTOMs. Cassie CorneauMang. of Investor Relations and Strategic Fin.Mr. Jonathan SchimmelVP of Global Support & Sales OperationsMs. Rebecca PortChief People OfficerMs. Ruth De Backer (Age 46)Chief Bus. Officer Mr. Jim Wilbur Ph.D.Chief Commercial OfficerMore ExecutivesKey CompetitorsPacific Biosciences of CaliforniaNASDAQ:PACBOlink Holding AB (publ)NASDAQ:OLKBio-Rad LaboratoriesNYSE:BIO.BBio-Rad LaboratoriesNYSE:BIOAvantorNYSE:AVTRView All CompetitorsInsiders & InstitutionsSerge SaxonovSold 2,602 sharesTotal: $143,266.12 ($55.06/share)Benjamin J HindsonSold 2,388 sharesTotal: $131,483.28 ($55.06/share)Justin J McanearSold 1,665 sharesTotal: $91,674.90 ($55.06/share)Capital Impact Advisors LLCBought 3,879 shares on 5/23/2023Ownership: 0.006%Ameriprise Financial Inc.Sold 5,704 shares on 5/22/2023Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions TXG Stock - Frequently Asked Questions Should I buy or sell 10x Genomics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TXG shares. View TXG analyst ratings or view top-rated stocks. What is 10x Genomics' stock price forecast for 2023? 12 Wall Street research analysts have issued 12-month price targets for 10x Genomics' stock. Their TXG share price forecasts range from $25.00 to $68.00. On average, they expect the company's stock price to reach $54.85 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View analysts price targets for TXG or view top-rated stocks among Wall Street analysts. How have TXG shares performed in 2023? 10x Genomics' stock was trading at $36.44 at the start of the year. Since then, TXG shares have increased by 49.8% and is now trading at $54.60. View the best growth stocks for 2023 here. When is 10x Genomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our TXG earnings forecast. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) released its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.06. The business had revenue of $134.29 million for the quarter, compared to analysts' expectations of $128.87 million. 10x Genomics had a negative net margin of 32.51% and a negative trailing twelve-month return on equity of 22.02%. 10x Genomics's quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.38) EPS. What ETFs hold 10x Genomics' stock? ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ARK Innovation ETF (ARKK), Invesco DWA Healthcare Momentum ETF (PTH), Principal Healthcare Innovators ETF (BTEC), First Trust Multi-Manager Large Growth ETF (MMLG) and ERShares Entrepreneurs ETF (ENTR). What guidance has 10x Genomics issued on next quarter's earnings? 10x Genomics updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $590.00 million-$610.00 million, compared to the consensus revenue estimate of $593.20 million. What is Serge Saxonov's approval rating as 10x Genomics' CEO? 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did 10x Genomics IPO? (TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager. What is 10x Genomics' stock symbol? 10x Genomics trades on the NASDAQ under the ticker symbol "TXG." Who are 10x Genomics' major shareholders? 10x Genomics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (7.59%), BlackRock Inc. (4.54%), FMR LLC (3.79%), ARK Investment Management LLC (3.60%), Sands Capital Management LLC (3.24%) and Brown Capital Management LLC (2.67%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 10x Genomics' stock price today? One share of TXG stock can currently be purchased for approximately $54.60. How much money does 10x Genomics make? 10x Genomics (NASDAQ:TXG) has a market capitalization of $6.34 billion and generates $516.41 million in revenue each year. The company earns $-166,000,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. How many employees does 10x Genomics have? The company employs 1,239 workers across the globe. How can I contact 10x Genomics? 10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The official website for the company is www.10xgenomics.com. The company can be reached via phone at 925-401-7300 or via email at investors@10xgenomics.com. This page (NASDAQ:TXG) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.